Rome, 31 January 2023. The following text summarises the speech by Valeria Viola, owner of Pharma Value, during the presentation of the 6th OSSFOR Annual Report
Nomos and Pharma Value have developed an in-depth document to analyse the AIFA reform defined in recent weeks in the Senate and understand its
ll 28 settembre 2022 la Conferenza Stato Regioni ha rinviato il parere (punto 7) per il Piano attività di AIFA 2022. Il piano individua 3 mission aziendali: garantire l’unitarietà
The horizon scanning activity for AIFA is strategic as it allows it to identify new, emerging health technologies in order to compare them with existing ones and replace them
Ginevra Mastroianni, Sara De Franceschi, Valeria Viola (Pharma Value) Law 648/1996 allows the dispensing of a drug that is not yet authorised or available in Italy
NOMOS Centro Studi Parlamentari and Pharma Value produced a special report on drug evaluation commissions, namely the Technical Scientific Commission and the
AIFA has published a communication on the update of national requirements to be included in the Blue Box. There is a major impact on the regulatory activities of companies in
Today ICMRA, the international coalition of health regulators from every region of the world, met. Within it are the regulatory agencies
The Italian pharmaceutical market environment, from regulatory to regulatory, has always been a highly changeable scenario, due to constant technological advances,
